Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma

Daratumumab, a human immunoglobulin G1 kappa monoclonal antibody that targets CD38, is currently approved as monotherapy and in varying combinations with approved anti-myeloma regimens in both newly diagnosed multiple myeloma and relapsed refractory multiple myeloma. Originally developed for intrave...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Hematol
Main Authors: Sanchez, Larysa, Richter, Joshua, Cho, Hearn Jay, Jagannath, Sundar, Madduri, Deepu, Parekh, Samir, Richard, Shambavi, Tam, Lowena, Verina, Daniel, Chari, Ajai
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2021
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841854/
https://ncbi.nlm.nih.gov/pubmed/33613930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720987075
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados